The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172).
E. De Azambuja
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline; Schering-Plough
M. Lemort
No relevant relationships to disclose
J. R. Rossari
No relevant relationships to disclose
C. Moulin
No relevant relationships to disclose
A. Buttice
No relevant relationships to disclose
V. D'hondt
No relevant relationships to disclose
F. Lebrun
No relevant relationships to disclose
Y. Lalami
No relevant relationships to disclose
F. Cardoso
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
C. Sotiriou
No relevant relationships to disclose
T. Gil
No relevant relationships to disclose
D. Devriendt
No relevant relationships to disclose
W. J. Marinus
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
M. Paesmans
No relevant relationships to disclose
M. Piccart
Honoraria - GlaxoSmithKline
A. Awada
No relevant relationships to disclose